Julie M. Cherrington

Julie M. Cherrington, Ph.D. joined Mirati’s Board of Directors in June 2019. She is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®.

Dr. Cherrington is currently the President and Chief Executive Officer of Arch Oncology, a clinical-stage immuno-oncology company developing novel anti-CD47 mAbs. Previously, she has served as President and Chief Executive Officer at several other oncology companies, including Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics, a company advancing targeted kinase inhibitors for the treatment of cancer. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.